Patents Examined by Sean M Basquill
-
Patent number: 11992559Abstract: Extended-release microsphere formulations comprising lurasidone are provided. In one aspect, the microsphere formulations are characterized in that the lurasidone is released in vivo in humans over a period of about 30 days. Methods for making and using the formulations are also provided.Type: GrantFiled: February 24, 2022Date of Patent: May 28, 2024Assignee: Oakwood Laboratories, LLCInventors: Colin Spencer, Griffin Beyer, Tracy Richey, Mark Smith, Nicholas DeLucia
-
Patent number: 11986445Abstract: A synthetic nutritional composition comprising choline for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.Type: GrantFiled: December 13, 2016Date of Patent: May 21, 2024Assignee: Societe des Produits Nestle S.A.Inventors: Nora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai
-
Patent number: 11970583Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.Type: GrantFiled: August 25, 2021Date of Patent: April 30, 2024Assignee: Starpharma Pty Ltd.Inventors: David James Owen, Brian Devlin Kelly
-
Patent number: 11964049Abstract: Provided is a composition for oral administration, the composition including: a dispersion medium including: an aqueous solution; and a dispersed phase including: a population of particles, each particle including: a core including: a first active ingredient; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a lipophilic carrier; and a plurality of emulsifying agents; wherein the particle retards the release of the first active ingredient after consumption.Type: GrantFiled: March 18, 2022Date of Patent: April 23, 2024Assignee: Nulixir Inc.Inventor: Ehsan Moaseri
-
Patent number: 11964047Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.Type: GrantFiled: June 8, 2023Date of Patent: April 23, 2024Assignee: ETERNATEAR, INC.Inventors: Timothy R. Willis, Ralph P. Stone
-
Patent number: 11944618Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent the agent linked to the polymer via a linking group containing a cleavable moiety.Type: GrantFiled: April 11, 2022Date of Patent: April 2, 2024Assignee: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas, Michael David Bentley
-
Patent number: 11931415Abstract: A composition comprises: a base oil; an additive; and a drug. The additive has segments which are conjugated, e.g. covalently linked, together. A first segment facilitates solubility in the base oil, whereas a second segment facilitates drug solubility and/or modifies drug release or other behaviour. The first segment may for example comprise a poly(dimethylsiloxane)-containing moiety. The second segment may for example resemble a drug molecule. The composition may for example be used as a tamponade or as a component for a tamponade administered to the eye.Type: GrantFiled: August 9, 2017Date of Patent: March 19, 2024Assignee: THE UNIVERSITY OF LIVERPOOLInventors: Victoria Kearns, Helen Cauldbeck, Steve Rannard, Rachel Williams, Maude Le Hellaye
-
Patent number: 11931327Abstract: An object of the present invention is to provide a medicine that can simply treat and/or prevent a retinal degenerative disease associated with photoreceptor degeneration, including retinitis pigmentosa. The solution is to provide an agent for treating and/or preventing a retinal degenerative disease associated with photoreceptor degeneration, containing a compound having a retinoic acid receptor agonistic activity (for example, tamibarotene, tamibarotene methyl ester, tamibarotene ethyl ester, tazarotene, tazarotenic acid, adapalene, palovarotene, retinol, isotretinoin, alitretinoin, etretinate, acitretin or bexarotene) or a salt thereof.Type: GrantFiled: July 3, 2018Date of Patent: March 19, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Naoki Tsuji, Masumi Ueno
-
Amide-functionalized polymerization initiators and their use in the manufacture of ophthalmic lenses
Patent number: 11912800Abstract: Provided are compounds that may function as functionalized polymerization initiators, for instance in the manufacture of ophthalmic lenses, and to methods of such manufacture. The compounds are of formula I: wherein R1, R2, R3, R4, R5, T, p, q, and n are as defined herein.Type: GrantFiled: August 22, 2022Date of Patent: February 27, 2024Assignee: Johnson & Johnson Vision Care, Inc.Inventors: Michael F. Widman, Ghulam Maharvi, Shivkumar Mahadevan, Azaam Alli, Alexander Guzman, Xin Wei, Minghan Chen -
Patent number: 11890330Abstract: The present invention relates to methods of treating or preventing a bacterial disease or infection, antibacterial compositions, and antibacterial surfaces, including an isolated polypeptide comprising an enzymatically active domain (EAD) of a Bacillus bacteriophage endolysin.Type: GrantFiled: May 16, 2019Date of Patent: February 6, 2024Assignees: University of Maryland, College Park, The United States of America, as Represented by the Secretary of the NavyInventors: Daniel C. Nelson, Irina V. Etobayeva
-
Patent number: 11891726Abstract: The present invention relates to fibers comprising a polyesteramide (PEA) having a chemical formula described by structural formula (IV), wherein m+p varies from 0.9-0.1 and q varies from 0.1 to 0.9; m+p+q=1 whereby m or p could be 0; n is about 5 to about 300; (pref.Type: GrantFiled: July 21, 2021Date of Patent: February 6, 2024Assignee: DSM IP ASSETS B.V.Inventors: Mirian Hendrika Jacoba Gillisen-Van Der Vight, Jens Christoph Thies, Gueorgui Mihov
-
Patent number: 11883372Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.Type: GrantFiled: March 15, 2022Date of Patent: January 30, 2024Assignee: MEXICHEM FLUOR S.A. DE C.V.Inventors: Stuart Corr, Timothy James Noakes
-
Patent number: 11883541Abstract: The presently disclosed subject matter provides compositions and methods for administering a nanoparticle or microparticle and a therapeutic agent to the suprachoroidal space in the eye.Type: GrantFiled: October 2, 2018Date of Patent: January 30, 2024Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Peter A. Campochiaro, Jordan Green, Jayoung Kim, Jikui Shen
-
Patent number: 11872327Abstract: A medical device including a silicone hydrogel which is less likely to harden due to drying, and which is less likely to cause stimulation at a site in contact with a human body, is disclosed. The medical device includes a silicone hydrogel satisfying the following conditions: (1) the water content in hydrous state is within the range of 10% by mass to 70% by mass; (2) the content of silicon atoms with respect to the total mass in dry state is within the range of 8% by mass to 30% by mass; and (3) the tensile elastic modulus in dry state is within the range of 0.1 MPa to 3.5 MPa.Type: GrantFiled: April 19, 2018Date of Patent: January 16, 2024Assignee: Toray Industries, Inc.Inventors: Tomohiro Kato, Masataka Nakamura
-
Patent number: 11865269Abstract: Medical devices including moisture control/barrier layers over hydrophilic materials wherein the moisture control layers allow selective ingress into and egress from the hydrophilic materials. The barrier layers may also be physical barrier layers that protect the hydrophilic materials from contaminates.Type: GrantFiled: September 10, 2018Date of Patent: January 9, 2024Assignee: Hollister IncorporatedInventor: David J. Farrell
-
Patent number: 11857701Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.Type: GrantFiled: May 22, 2023Date of Patent: January 2, 2024Assignee: Board Of Regents, The University Of Texas SystemInventors: Sarah Mayes, Christine E. Schmidt
-
Patent number: 11857634Abstract: A formulation includes a plurality of polymers including a hydrophobic polymer backbone (for example, formed via radical polymerization), a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one cationic group, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one hydrophilic polymer, a first therapeutic compound, and a second therapeutic compound, wherein the second therapeutic compound is different from the first therapeutic compound and includes a nucleic acid.Type: GrantFiled: April 20, 2019Date of Patent: January 2, 2024Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Song Li, Jingjing Sun, Yichao Chen, Yixian Huang, Yanhua Liu, Binfeng Lu
-
Patent number: 11833170Abstract: Provided are compounds, compositions, methods, and kits for increasing target specificity of a mannosylated carbohydrate polymeric therapeutic or diagnostic compound to reduce or eliminate localization of the mannosylated carbohydrate polymeric therapeutic or diagnostic compound to off-target sites. Mannosylated carbohydrate polymers are synthesized to be modified to be either polyanionic (i.e., net negatively charged) or electrostatically neutral, and using these polyanionic or neutral mannosylated carbohydrate polymers as competitors for polycationic (i.e., net positively charged) mannosylated carbohydrate polymers carrying small molecule drug payloads or imaging moieties to CD206 expressing cells in target tissues, such as tumors or other sites of inflammation.Type: GrantFiled: February 3, 2023Date of Patent: December 5, 2023Assignee: Navidea Biopharmaceuticals, Inc.Inventors: David A. Ralph, Jeffrey Scott Arnold
-
Patent number: 11833149Abstract: A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.Type: GrantFiled: January 10, 2022Date of Patent: December 5, 2023Assignee: OSI Pharmaceuticals, LLCInventors: Stanley C. Gill, Kenneth K. Iwata, Gregory J. Riely, Jun Wu, Helena Yu
-
Patent number: 11826348Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).Type: GrantFiled: June 29, 2021Date of Patent: November 28, 2023Assignee: MEXICHEM FLUOR S.A. DE C.V.Inventors: Stuart Corr, Timothy James Noakes